| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Helen Heslop | Q17386041 |
| Cliona M Rooney | Q96221187 | ||
| Teresa Manzo | Q56889156 | ||
| P2860 | cites work | Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 | Q24633445 |
| T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions | Q27680546 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Q29617590 | ||
| Reversal of tumor immune inhibition using a chimeric cytokine receptor | Q30580134 | ||
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 | ||
| Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease | Q33456742 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma | Q34018782 | ||
| Adoptive cell transfer as personalized immunotherapy for human cancer | Q34043643 | ||
| Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors | Q34205181 | ||
| Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma | Q34242449 | ||
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer | Q57152489 | ||
| Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients | Q74379461 | ||
| Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. | Q34273968 | ||
| Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation | Q34312922 | ||
| Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. | Q34501316 | ||
| Telomerase as a universal tumor-associated antigen for cancer immunotherapy | Q34535727 | ||
| Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. | Q34557946 | ||
| Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial | Q34623991 | ||
| Hodgkin lymphoma | Q34643277 | ||
| A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation | Q35012553 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response | Q35182795 | ||
| Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. | Q35563824 | ||
| CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo | Q35776868 | ||
| Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation | Q35849338 | ||
| Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype | Q35849686 | ||
| Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer | Q36059593 | ||
| Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections | Q36142490 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers | Q36403280 | ||
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy | Q36637039 | ||
| Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs | Q36757012 | ||
| Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients | Q36919619 | ||
| Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation | Q36962653 | ||
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. | Q37095348 | ||
| Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma | Q37690437 | ||
| Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect | Q37821337 | ||
| Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
| T-cell therapy in the treatment of post-transplant lymphoproliferative disease | Q38026758 | ||
| Immune checkpoint blockade in hematologic malignancies | Q38400922 | ||
| Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature | Q39220424 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells | Q44013424 | ||
| Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation | Q45370775 | ||
| Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. | Q45423535 | ||
| Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes | Q45551744 | ||
| Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders | Q45775663 | ||
| Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. | Q45885336 | ||
| P433 | issue | R1 | |
| P304 | page(s) | R67-73 | |
| P577 | publication date | 2015-07-09 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Antigen-specific T cell therapies for cancer | |
| P478 | volume | 24 |
| Q38758807 | CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia |
| Q39354519 | Current Perspective on In Vivo Molecular Imaging of Immune Cells. |
| Q39016336 | Current Trends and Alternative Scenarios in EBV Research |
| Q89783580 | Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells |
| Q58568313 | Discovery of rare cells from voluminous single cell expression data |
| Q55364522 | Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood. |
| Q36162660 | In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI. |
| Q92619924 | Multi-Objective Optimized Fuzzy Clustering for Detecting Cell Clusters from Single-Cell Expression Profiles |
| Q27313748 | PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model |
| Q59354898 | Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model |
| Q40221792 | Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. |
| Q38691172 | The immune system and cancer evasion strategies: therapeutic concepts |
| Q28075314 | Toxicity and management in CAR T-cell therapy |
| Q38959382 | Virus-Specific CD8+ T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression |
Search more.